Phase I pilot study of INT 0036 as a potential therapy for schizophrenia.
Phase of Trial: Phase I
Latest Information Update: 10 Nov 2014
At a glance
- Drugs INT 0036 (Primary) ; INT 0036
- Indications Schizophrenia
- Focus First in man; Pharmacokinetics
- 10 Nov 2014 New trial record
- 03 Nov 2014 Results published in an IntelGenx Corp. media release.